Idealp-Pharma Launches ‘Hit-To-Candidate’ Services
News Jun 20, 2008
Idealp-Pharma is launching fully integrated drug discovery and preclinical development services combining medicinal chemistry, cheminformatics, screening, early ADMET and preclinical development capabilities to speed up partner’s and client’s small molecules programs from biological target to firstin-man use.
According to Serge Petit, PhD, President and CEO, “Being a one-stop-shop company adds significant value because the lead optimization process involves iterative cycles for incremental optimization. The main advantages of our one-stop-shop service are to have access to all the experimental data, to be able to refocus the synthesis program and then to make the best decision for the lead optimization process in accordance with our customers' specifications.”
“Idealp-Pharma manages its customers' hit discovery and validation, hit-to-lead progression and lead-to-candidate process. Our aim is to deliver chemically and biologically validated hits, accelerating lead optimization and identying IND candidate for our customers”, said Serge Petit.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
New Speakers from Roche and Imperial College London Announced for SMi’s ADMET EventNews
SMi Group Reports: With less than 4 weeks left until the 13th annual ADMET Conference commences in London, SMi announces two new speakers joining the event.READ MORE